TG Therapeutics Inc (TGTX)

Gross profit margin

		Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019
Gross profit (ttm)	US$ in thousands	85,088	178,340	134,391	88,381	63,212	-76,772	-71,239	-67,327	-74,994	-93,703	-114,131	-94,831	-108,508	-110,897	-92,821	-107,698	-68,095	-36,113	-24,395	-15,455
Revenue (ttm)	US$ in thousands	262,359	340,582	280,254	222,343	180,883	18,875	6,331	2,784	5,025	6,961	7,912	6,689	4,406	2,414	907	152	152	152	152	152
Gross profit margin		32.43%	52.36%	47.95%	39.75%	34.95%	-406.74%	-1,125.24%	-2,418.35%	-1,492.42%	-1,346.11%	-1,442.51%	-1,417.72%	-2,462.73%	-4,593.91%	-10,233.85%	-70,853.95%	-44,799.34%	-23,758.55%	-16,049.34%	-10,167.76%

September 30, 2024 calculation

Gross profit margin = Gross profit (ttm) ÷ Revenue (ttm)
= $85,088K ÷ $262,359K
= 32.43%

TG Therapeutics Inc's gross profit margin has shown significant fluctuations over the past few quarters. The company's gross profit margin was notably positive in the recent quarters, ranging from 32.43% to 52.36%. However, there were anomalies in the historical data, particularly in the quarters ending in June 2023 and March 2023, where the gross profit margin was extremely negative, primarily driven by unexpected expenses or losses that severely impacted the company's profitability.

It is essential for TG Therapeutics Inc to carefully analyze the factors contributing to the negative gross profit margins in the past to prevent such occurrences in the future and maintain a healthy financial performance. The positive trend in the most recent quarters is encouraging, indicating potentially improved efficiency in the company's cost structure or revenue generation. Continued monitoring and strategic decision-making will be crucial for sustaining and building upon this positive momentum.